Amyloid β conformation in aqueous environment

Current Alzheimer Research

Volumn 5, Issue 6, 2008, Pages 540-547

  Takano, K ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amyloid; Fusion technique; Monomer; Structure

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 10 24; AMYLOID BETA PROTEIN 28 42; METAL ION; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AQUEOUS SOLUTION; CRYSTAL STRUCTURE; HUMAN; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; REVIEW; SIMULATION; STRUCTURE ANALYSIS; THERMOPHILE;

AMYLOID BETA-PROTEIN; ANIMALS; CRYSTALLIZATION; HUMANS; MEMBRANES, ARTIFICIAL; PROTEIN CONFORMATION; PROTEIN FOLDING; SOLUTIONS; WATER;

EID: 58049195818     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508786898424     Document Type: Review

References (127)

1. Tan SY and Pepys MB. Amyloidosis. Histopathology 25: 403-414 (1994).
2. Carrell RW and Lomas DA. Conformational disease. Lancet 350: 134-138 (1997).
3. Pepys MB. Amyloid, familial Mediterranean fever, and acute phase response. In "The Oxford textbook of medicine, 3rd ed, vol. 2" (Eds: Weatherall DJ, Ledingham JGG, Warell DA). Oxford University Press, Oxford, p. 1512-1524 (1996).
4. Iqbal K, Winblad B, Nishiyama T, Takeda M and Wisniewski HM. "Alzheimer's Disease: Biology, Diagnosis, and Therapeutics" John Wiley & Sons, New York (1997).
5. Smith MA. Alzheimer disease. Internat Rev Neurobiol 42: 1-54 (1998).
6. Glenner GG. Amyloid deposits and amyloidosis: the β-fibrilloses. N Engl J Med 302: 1283-1292 (1980).
7. Glenner GG and Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-901 (1984).
8. Teplow DB. Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid 5: 121-142 (1998).
9. Selkoe DJ. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8: 447-453 (1998).
10. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
11. Kim JE and Lee M. Fullerene inhibits β-amyloid peptide aggregation. Biochem Biophys Res Commun 303: 576-579 (2003).
12. Hardy J and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-38 (1991).
13. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, et al. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271: 20631-20635 (1996).
14. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Aβ 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453 (1998).
15. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96: 3228-3233 (1999).
16. Walsh DM and Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44: 181-193 (2004).
17. Townsend M, Shankar GM, Mehta T, Walsh DM and Selkoe DJ. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572: 477-492 (2006).
18. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440: 352-357 (2006).
19. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castaño EM and Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4: 822-826 (1998).
20. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, et al. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 90: 10836-10840 (1993).
21. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB and Teplow DB. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100: 330-335 (2003).
22. Bitan G, Vollers SS and Teplow DB. Elucidation of primary structure elements controlling early amyloid β-protein oligomerization. J Biol Chem 278: 34882-34889 (2003).
23. Jarrett JT, Berger EP and Lansbury PT Jr. The C-terminus of the β protein is critical in amyloidogenesis. Ann NY Acad Sci 695: 144-148 (1993).
24. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, et al. Amyloid β protein (Aβ) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43). J Biol Chem 270: 7013-7016 (1995).
25. El-Agnaf OM, Mahil DS, Patel BP and Austen BM. Oligomerization and toxicity of β-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun 273: 1003-1007 (2000).
26. Barrow CJ, Yasuda A, Kenny PT and Zagorski MG. Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol 225: 1075-1093 (1992).
27. Sticht H, Bayer P, Willbold D, Dames S, Hilbich C, Beyreuther K, et al. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur J Biochem 233: 293-298 (1995).
28. Soto C, Castaño EM, Frangione B and Inestrosa NC. The β-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation. J Biol Chem 270: 3063-3067 (1995).
29. Fletcher TG and Keire DA. The interaction of β-amyloid protein fragment (12-28) with lipid environments. Protein Sci 6: 666-675 (1997).
30. Shao H, Jao S, Ma K and Zagorski MG. Solution structures of micelle-bound amyloid β-(1-40) and β-(1-42) peptides of Alzheimer's disease. J Mol Biol 285: 755-773 (1999).
31. Harper JD and Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385-407 (1997).
32. Wood SJ, Maleeff B, Hart T and Wetzel R. Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Aβ. J Mol Biol 256: 870-877 (1996).
33. Wood SJ, MacKenzie L, Maleeff B, Hurle MR and Wetzel R. Selective inhibition of Aβ fibril formation. J Biol Chem 271: 4086-4092 (1996).
34. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8: 101-106 (1998).
35. Whittemore NA, Mishra R, Kheterpal I, Williams AD, Wetzel R and Serpersu EH. Hydrogen-deuterium (H/D) exchange mapping of Aβ 1-40 amyloid fibril secondary structure using nuclear magnetic resonance spectroscopy. Biochemistry 44: 4434-4441 (2005).
36. Morozova-Roche LA, Zurdo J, Spencer A, Noppe W, Receveur V, Archer DB, et al. Amyloid fibril formation and seeding by wildtype human lysozyme and its disease-related mutational variants. J Struct Biol 130: 339-351 (2000).
37. Serpell LC and Smith JM. Direct visualisation of the β-sheet structure of synthetic Alzheimer's amyloid. J Mol Biol 299: 225-231 (2000).
38. Goldsbury C, Frey P, Olivieri V, Aebi U and Müller SA. Multiple assembly pathways underlie amyloid-β fibril polymorphisms. J Mol Biol 352: 282-298 (2005).
39. Mastrangelo IA, Ahmed M, Sato T, Liu W, Wang C, Hough P, et al. High-resolution atomic force microscopy of soluble Aβ42 oligomers. J Mol Biol 358: 106-119 (2006).
40. Serpell LC. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 1502: 16-30 (2000).
41. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, et al. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99: 16742-16747 (2002).
42. Petkova AT, Yau WM and Tycko R. Experimental constraints on quaternary structure in Alzheimer's β-amyloid fibrils. Biochemistry 45: 498-512 (2006).
43. Jarrett JT, Berger EP and Lansbury PT Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697 (1993).
44. Hilbich C, Kisters-Woike B, Reed J, Masters CL and Beyreuther K. Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease. J Mol Biol 218: 149-163 (1991).
45. Santini S, Mousseau N and Derreumaux P. In silico assembly of Alzheimer's Aβ16-22 peptide into β-sheets. J Am Chem Soc 126: 11509-11516 (2004).
46. Santini S, Wei G, Mousseau N and Derreumaux P. Pathway complexity of Alzheimer's β-amyloid Aβ16-22 peptide assembly. Structure 12: 1245-1255 (2004).
47. Klimov DK, Straub JE and Thirumalai D. Aqueous urea solution destabilizes Aβ(16-22) oligomers. Proc Natl Acad Sci USA 101: 14760-14765 (2004).
48. Takano K, Endo S, Mukaiyama A, Chon H, Matsumura H, Koga Y, et al. Structure of amyloid β fragments in aqueous environments. FEBS J 273: 150-158 (2006).
49. Takano K, Takeda Y, You DJ, Mukaiyama A, Matsumura H, Koga Y, et al. Crystal structure of amyloid beta fragment. New Trends Alzheimer Parkinson Disord 153-156 (2008).
50. Ohnishi S and Takano K. Amyloid fibrils from the viewpoint of protein folding. Cell Mol Life Sci 61: 511-524 (2004).
51. Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362: 553-557 (1993).
52. Gillmore JD, Booth DR, Madhoo S, Pepys MB and Hawkins PN. Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant 14: 2639-2644 (1999).
53. Valleix S, Drunat S, Philit JB, Adoue D, Piette JC, Droz D, et al. Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family. Kidney Int 61: 907-912 (2002).
54. Yazaki M, Farrell SA and Benson MD. A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis. Kidney Int 63: 1652-1657 (2003).
55. Funahashi J, Takano K, Ogasahara K, Yamagata Y and Yutani K. The structure, stability, and folding process of amyloidogenic mutant human lysozyme. J Biochem 120: 1216-1223 (1996).
56. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385: 787-793 (1997).
57. Takano K, Funahashi J and Yutani K. The stability and folding process of amyloidogenic mutant human lysozymes. Eur J Biochem 268:155-159 (2001).
58. Goda S, Takano K, Yamagata Y, Maki S, Namba K and Yutani K. Elongation in a β-structure promotes amyloid-like fibril formation of human lysozyme. J Biochem 132: 655-661 (2002).
59. Guijarro JI, Sunde M, Jones JA, Campbell ID and Dobson CM. Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci USA 95: 4224-4228 (1998).
60. Goda S, Takano K, Yamagata Y, Nagata R, Akutsu H, Maki S, et al. Amyloid protofilament formation of hen egg lysozyme in highly concentrated ethanol solution. Protein Sci 9: 369-375 (2000).
61. Fändrich M, Fletcher MA and Dobson CM. Amyloid fibrils from muscle myoglobin. Nature 410: 165-166 (2001).
62. Coles M, Bicknell W, Watson AA, Fairlie DP and Craik DJ. Solution structure of amyloid β-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 37: 11064-11077 (1998).
63. Rodziewicz-Motowidło S, Juszczyk P, Kołodziejczyk AS, Sikorska E, Skwierawska A, Oleszczuk M, et al. Conformational solution studies of the SDS micelle-bound 11-28 fragment of two Alzheimer's β-amyloid variants (E22K and A21G) using CD, NMR, and MD techniques. Biopolymers 87: 23-39 (2007).
64. Talafous J, Marcinowski KJ, Klopman G and Zagorski MG. Solution structure of residues 1-28 of the amyloid β-peptide. Biochemistry 33: 7788-7796 (1994).
65. Barrow CJ and Zagorski MG. Solution structures of β peptide and its constituent fragments: relation to amyloid deposition. Science 253: 179-182 (1991).
66. Laczkó I, Holly S, Kónya Z, Soós K, Varga JL, Hollósi M, et al. Conformational mapping of amyloid peptides from the putative neurotoxic 25-35 region. Biochem Biophys Res Commun 205: 120-126 (1994).
67. Shen CL, Fitzgerald MC and Murphy RM. Effect of acid predissolution on fibril size and fibril flexibility of synthetic β-amyloid peptide. Biophys J 67: 1238-1246 (1994).
68. Clippingdale AB, Wade JD and Barrow CJ. The amyloid-β peptide and its role in Alzheimer's disease. J Pept Sci 7: 227-249 (2001).
69. Lichtenthaler SF, Wang R, Grimm H, Uljon SN, Masters CL and Beyreuther K. Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci USA 96: 3053-3058 (1999).
70. Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D'Ursi AM, Temussi PA, et al. Solution structure of the Alzheimer amyloid β-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem 269: 5642-5648 (2002).
71. Tomaselli S, Esposito V, Vangone P, van Nuland NA, Bonvin AM, Guerrini R, et al. The α-to-β conformational transition of Alzheimer's Aβ-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of β conformation seeding. Chembiochem 7: 257-267 (2006).
72. D'Ursi AM, Armenante MR, Guerrini R, Salvadori S, Sorrentino G and Picone D. Solution structure of amyloid β-peptide (25-35) in different media. J Med Chem 47: 4231-4238 (2004).
73. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 265: 1464-1467 (1994).
74. Bush AI, Pettingell WH Jr, Paradis MD and Tanzi RE. Modulation of Aβ adhesiveness and secretase site cleavage by zinc. J Biol Chem 269: 12152-12158 (1994).
75. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J Neurochem 61: 1171-1174 (1993).
76. Stellato F, Menestrina G, Serra MD, Potrich C, Tomazzolli R, Meyer-Klaucke W, et al. Metal binding in amyloid β-peptides shows intra- and inter-peptide coordination modes. Eur Biophys J 35: 340-351 (2006).
77. Dong J, Shokes JE, Scott RA and Lynn DG. Modulating amyloid self-assembly and fibril morphology with Zn(II). J Am Chem Soc 128: 3540-3542 (2006).
78. Raffa DF, Gómez-Balderas R, Brunelle P, Rickard GA and Rauk A. Ab initio model studies of copper binding to peptides containing a His-His sequence: relevance to the β-amyloid peptide of Alzheimer's disease. J Biol Inorg Chem 10: 887-902 (2005).
79. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23: 1031-1038 (2002).
80. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE and Bush AI. Trace metal contamination initiates the apparent autoaggregation, amyloidosis, and oligomerization of Alzheimer's Aβ peptides. J Biol Inorg Chem 9: 954-960 (2004).
81. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL and Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52 (1998).
82. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A and Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with β-amyloid deposits in Alzheimer's disease. J Struct Biol 155: 30-37 (2006).
83. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, et al. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J Biol Chem 274: 23223-23228 (1999).
84. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, et al. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271: 20631-20635 (1996).
85. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 641-642 (2001).
86. 2+-sensitive peptides. Chembiochem 9: 531-536 (2008).
87. Liu ST, Howlett G and Barrow CJ. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the Aβ peptide of Alzheimer's disease. Biochemistry 38: 9373-9378 (1999).
88. Atwood CS, Martins RN, Smith MA and Perry G. Senile plaque composition and posttranslational modification of amyloid-β peptide and associated proteins. Peptides 23: 1343-1350 (2002).
89. Huang J, Yao Y, Lin J, Ye YH, Sun WY and Tang WX. The solution structure of rat Aβ-(1-28) and its interaction with zinc ion: insights into the scarcity of amyloid deposition in aged rat brain. J Biol Inorg Chem 9: 627-635 (2004).
90. 2+ interactions with rat and human β-amyloid (1-28) peptides in water-micelle environment. J Phys Chem B 112: 100-109 (2008).
91. Miura T, Suzuki K, Kohata N and Takeuchi H. Metal binding modes of Alzheimer's amyloid β-peptide in insoluble aggregates and soluble complexes. Biochemistry 39: 7024-7031 (2000).
92. Syme CD, Nadal RC, Rigby SE and Viles JH. Copper binding to the amyloid-β (Aβ) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Aβ-(1-28): insights from a range of complementary spectroscopic techniques. J Biol Chem 279: 18169-18177 (2004).
93. Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, et al. Copper-mediated amyloid-β toxicity is associated with an intermolecular histidine bridge. J Biol Chem 281: 15145-15154 (2006).
94. Lim KH, Kim YK and Chang YT. Investigations of the molecular mechanism of metal-induced Aβ (1-40) amyloidogenesis. Biochemistry 46: 13523-13532 (2007).
95. 2+ binding site in amyloid-β. Biochemistry 44: 5478-5487 (2005).
96. Huang X, Atwood CS, Moir RD, Hartshorn MA, Vonsattel JP, Tanzi RE, et al. Zinc-induced Alzheimer's Aβ1-40 aggregation is mediated by conformational factors. J Biol Chem 272: 26464-26470 (1997).
97. Talmard C, Guilloreau L, Coppel Y, Mazarguil H and Faller P. Amyloid-β peptide forms monomeric complexes with Cu(II) and Zn(II) prior to aggregation. Chembiochem 8: 163-165 (2007).
98. Yu H, Ren J and Qu X. Different hydration changes accompanying copper and zinc binding to amyloid β-Peptide: water contribution to metal binding. Chembiochem 9: 879-882 (2008).
99. Ricchelli F, Drago D, Filippi B, Tognon G and Zatta P. Aluminum-triggered structural modifications and aggregation of β-amyloids. Cell Mol Life Sci 62: 1724-1733 (2005).
100. Drago D, Bettella M, Bolognin S, Cendron L, Scancar J, Milacic R, et al. Potential pathogenic role of β-amyloid1-42-aluminum complex in Alzheimer's disease. Int J Biochem Cell Biol 40: 731-746 (2008).
101. Massi F, Peng JW, Lee JP and Straub JE. Simulation study of the structure and dynamics of the Alzheimer's amyloid peptide congener in solution. Biophys J 80: 31-44 (2001).
102. Daidone I, Simona F, Roccatano D, Broglia RA, Tiana G, Colombo G, et al. β-hairpin conformation of fibrillogenic peptides: structure and α-β transition mechanism revealed by molecular dynamics simulations. Proteins 57: 198-204 (2004).
103. Han D, Wang H and Yang P. Molecular modeling of zinc and copper binding with Alzheimer's amyloid β-peptide. Biometals 21: 189-196 (2008).
104. Colombo G, Daidone I, Gazit E, Amadei A and Di Nola A. Molecular dynamics simulation of the aggregation of the core-recognition motif of the islet amyloid polypeptide in explicit water. Proteins 59: 519-527 (2005).
105. Suzuki S, Galzitskaya OV, Mitomo D and Higo J. General dynamic properties of Aβ12-36 amyloid peptide involved in Alzheimer's disease from unfolding simulation. J Biochem 136: 583-594 (2004).
106. 21-30 region of amyloid β-protein (Aβ) studied in silico. Proc Natl Acad Sci USA 102: 6015-6020 (2005).
107. Baumketner A, Bernstein SL, Wyttenbach T, Lazo ND, Teplow DB, Bowers MT, et al. Structure of the 21-30 fragment of amyloid β-protein. Protein Sci 15: 1239-1247 (2006).
108. Baumketner A, et al. The structure of the Alzheimer amyloid β10-35 peptide probed through replica-exchange molecular dynamics simulations in explicit solvent. J Mol Biol 366: 275-285 (2006).
109. Xu Y, Shen J, Luo X, Zhu W, Chen K, Ma J, et al. Conformational transition of amyloid β-peptide. Proc Natl Acad Sci USA 102: 5403-5407 (2005).
110. Flöck D, Colacino S, Colombo G and Di Nola A. Misfolding of the amyloid β-protein: a molecular dynamics study. Proteins 62: 183-192 (2006).
111. Urbanc B, Cruz L, Yun S, Buldyrev SV, Bitan G, Teplow DB, et al. In silico study of amyloid β-protein folding and oligomerization. Proc Natl Acad Sci USA 101: 17345-17350 (2004).
112. Teplow DB, Lazo ND, Bitan G, Bernstein S, Wyttenbach T, Bowers MT, et al. Elucidating amyloid β-protein folding and assembly: A multidisciplinary approach. Acc Chem Res 39: 635-645 (2006).
113. Sgourakis NG, Yan Y, McCallum SA, Wang C and Garcia AE. The Alzheimer's peptides Aβ40 and 42 adopt distinct conformations in water: a combined MD / NMR study. J Mol Biol 368: 1448-1457 (2007).
114. Lee JP, Stimson ER, Ghilardi JR, Mantyh PW, Lu YA, Felix AM, et al. 1H NMR of Aβ amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. Biochemistry 34: 5191-5200 (1995).
115. Zhang S, Casey N and Lee JP. Residual structure in the Alzheimer's disease peptide: probing the origin of a central hydrophobic cluster. Fold Des 3: 413-422 (1998).
116. Zhang S, Iwata K, Lachenmann MJ, Peng JW, Li S, Stimson ER, et al. The Alzheimer's peptide Aβ adopts a collapsed coil structure in water. J Struct Biol 130: 130-141 (2000).
117. Jarvet J, Damberg P, Bodell K, Eriksson LEG and Gräslund A. Reversible random coil to β-sheet transition and the early stage of aggregation of the Aβ(12-28) fragment from the Alzheimer peptide. J Am Chem Soc 122: 4261-4268 (2000).
118. Jarvet J, Damberg P, Danielsson J, Johansson I, Eriksson LE and Gräslund A. A left-handed 31 helical conformation in the Alzheimer Aβ(12-28) peptide. FEBS Lett 555: 371-374 (2003).
119. 1-helix, β-strand and random coil secondary structures. FEBS J 272: 3938-3949 (2005).
120. ox. Eur J Biochem 268: 5930-5936 (2001).
121. Yan Y and Wang C. Aβ42 is more rigid than Aβ40 at the C terminus: implications for Aβ aggregation and toxicity. J Mol Biol 364: 853-862 (2006).
122. Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, et al. Solution NMR studies of the Aβ(1-40) and Aβ(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc 126: 1992-2005 (2004).
123. Soto C, Brañes MC, Alvarez J and Inestrosa NC. Structural determinants of the Alzheimer's amyloid β-peptide. J Neurochem 63: 1191-1198 (1994).
124. Morimoto A, Irie K, Murakami K, Masuda Y, Ohigashi H, Nagao M, et al. Analysis of the secondary structure of β-amyloid (Aβ42) fibrils by systematic proline replacement. J Biol Chem 279: 52781-52788 (2004).
125. Irie K, Murakami K, Masuda Y, Morimoto A, Ohigashi H, Hara H, et al. The toxic conformation of the 42-residue amyloid β peptide and its relevance to oxidative stress in Alzheimer's disease. Mini Rev Med Chem 7: 1001-1008 (2007).
126. Karr JW and Szalai VA. Cu(II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer's Disease amyloid-β peptide. Biochemistry 47: 5006-5016 (2008).
127. Williams AD, Portelius E, Kheterpal I, Guo JT, Cook KD, Xu Y, et al. Mapping aβ amyloid fibril secondary structure using scanning proline mutagenesis. J Mol Biol 335: 833-842 (2004).